GLP-1 AND GIP REVOLUTION
DOI:
https://doi.org/10.22551/4d5cym27Keywords:
GLP-1, GIP REVOLUTIONAbstract
Obesity is a chronic, relapsing, and multifaceted condition anticipated to impact around fifty percent of the United States population by 2030. Current estimates indicate that 650 million adults and 340 million children and adolescents (ages 5-19 y.o.) worldwide are affected by obesity (1). Alongside the markedly rising incidence, obesity carries substantial medical and economic consequences for both individuals and nations. Obesity costs the U.S. $480.7 billion in healthcare and an additional $1.24 trillion in lost economic output. Various therapies have been established to facilitate weight loss, including lifestyle modifications involving nutrition, with or without exercise and/or behavioral therapy, anti-obesity drugs (AOMs), endoscopic and surgical procedures. The most common AOMs, such as glucagon-like peptide-1 receptor agonist (GLP-1 RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs) have demonstrated substantial weight loss results and are gaining popularity as therapy choices. The Food and Drug Administration (FDA) approved the use of the GLP-1 receptor agonist Liraglutide for the management of overweight and obesity in 2014, followed by Semaglutide in 2021, and the combined GLP-1/GIP receptor agonist Tirzepatide in 2023 (3).
References
1. Sørensen TIA, Martinez AR, Jørgensen TSH. Epidemiology of Obesity. Handb Exp Pharmacol 2022; 274: 3-27.
2. Waters H and Graf M. America’s obesity crisis: the health and economic impact of excess weight. Miliken Institute 2018; 1-24.
3. Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonist for obesity: Weight loss outcomes, tolera-bility, side effects, and risks. Obes Pillars 2024; 12: 100127.
4. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373(1): 11-22.
5. Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384(11): 989-1002.
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387(3): 205-216.
7. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associ-ated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 2023; 330(18): 1795-1797.
8. Yao R, Gala KS, Ghusn W, Abboud DM, Wallace FK, Vargas EJ. Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy. Am J Gastroenterol. 2024; 119(6): 1154-1157.
9. Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab; 22(12): 2487-2492.
10. Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. J Lipid Atheroscler 2023; 12(3): 213-222.
11. Albahli OM, et al. The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia. Cureus 2024; 16; 7.
12. Cummings JL, Atri A, Feldman HH, et al. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimers Res Ther 2025; 17(1):14.
13. Lecis D, Prandi FR, Barone L, et al. Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born? Biomolecules 2023;13(12): 1695.
14. Ruder K. As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging. JAMA 2023; 330(22): 2140-2142.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 The Medical-Surgical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
